XNASBJDX
Market cap2mUSD
Dec 24, Last price
3.63USD
1D
0.13%
1Q
2,408.56%
IPO
-99.54%
Name
Bluejay Diagnostics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
-100.00%
Net income
-10m
L+7.87%
CFO
-8m
L+7.39%
Profile
Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 249 | ||||
Cost of revenue | 11,092 | 9,567 | 3,376 | ||
Unusual Expense (Income) | |||||
NOPBT | (11,092) | (9,318) | (3,376) | ||
NOPBT Margin | |||||
Operating Taxes | (69) | 241 | |||
Tax Rate | |||||
NOPAT | (11,092) | (9,249) | (3,617) | ||
Net income | (9,954) 7.87% | (9,228) 147.42% | (3,730) 231.32% | ||
Dividends | (18) | ||||
Dividend yield | 0.08% | ||||
Proceeds from repurchase of equity | 160 | 29 | 32 | ||
BB yield | -11.95% | -0.38% | -0.15% | ||
| Debt | |||||
Debt current | 163 | 169 | |||
Long-term debt | 543 | 817 | |||
Deferred revenue | |||||
Other long-term liabilities | 12 | 16 | 341 | ||
Net debt | (1,503) | (9,130) | (19,048) | ||
| Cash flow | |||||
Cash from operating activities | (8,314) | (7,742) | (4,367) | ||
CAPEX | (704) | (1,199) | (24) | ||
Cash from investing activities | (704) | (1,199) | (24) | ||
Cash from financing activities | 1,112 | 8 | 22,526 | ||
FCF | (10,812) | (9,835) | (4,476) | ||
| Balance | |||||
Cash | 2,209 | 10,115 | 19,048 | ||
Long term investments | |||||
Excess cash | 2,209 | 10,103 | 19,048 | ||
Stockholders' equity | (26,951) | (16,995) | (7,693) | ||
Invested Capital | 30,211 | 29,045 | 28,074 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 137 | 126 | 53 | ||
Price | 9.76 -83.94% | 60.78 -85.16% | 409.60 | ||
Market cap | 1,338 -82.54% | 7,660 -64.89% | 21,817 | ||
EV | (165) | (1,469) | 23,788 | ||
EBITDA | (10,311) | (9,011) | (3,230) | ||
EV/EBITDA | 0.02 | 0.16 | |||
Interest | 21 | 367 | |||
Interest/NOPBT | |||||